Biomerica, Inc. Stock Hits New 52-Week Low at $1.59

Biomerica, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.59 as of July 21, 2026. This decline marks a significant downturn for the company, which has seen its stock price plummet by 64.47% over the past year, contrasting sharply with the S&P 500's performance of 19.09% during the same period. The company's market capitalization stands at approximately USD 6 million, reflecting its microcap status. Biomerica has been grappling with financial difficulties, evidenced by a negative return on equity of -90.76% and a lack of profitability, as indicated by its loss-making position. The firm has also reported a concerning annual decline in net sales of -7.03% and an operating profit decrease of -3.45% over the last five years. Additionally, institutional investors have reduced their stakes in Biomerica by 1.27% in the last quarter, now holding 11.95% of the company. This trend may signal a cautious outlook among larger investors regarding Biomerica's financial health and market position.